Clinical Trials
42 trialsNCT05839600 2026-05-22
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
Boehringer Ingelheim
Phase 1 Terminated
NCT02597036 2025-10-23
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT05976334 2025-10-06
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
Takeda
Phase 1 Terminated
NCT04642365 2025-05-21
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
Hoffmann-La Roche
Phase 1 Terminated
NCT02240238 2025-01-22
Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
NanoCarrier Co., Ltd.
Phase 1/2 Completed
NCT03477175 2025-01-07
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
Eisai Inc.
Phase 2 Completed
NCT00828919 2024-12-03
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
Pfizer
Phase NA Completed
NCT02699515 2024-11-18
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT01127178 2024-10-10
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1 Terminated
NCT01286467 2024-03-06
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
Pfizer
Phase 1 Completed
NCT04158583 2024-03-04
A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT01190644 2023-11-29
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT03225105 2023-11-22
M3541 in Combination With Radiotherapy in Solid Tumors
EMD Serono
Phase 1 Terminated
NCT00648648 2023-09-21
MK-1775-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02426892 2023-04-18
Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02598960 2023-03-06
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02593786 2022-10-24
CheckMate 077
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02639546 2022-09-16
iMATRIXcobi
Hoffmann-La Roche
Phase 1/2 Completed
NCT02660034 2021-12-06
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT01748825 2021-07-26
AZD1775 for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02533674 2021-06-11
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT03264066 2021-05-11
A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
Hoffmann-La Roche
Phase 2 Completed
NCT02587962 2021-01-14
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Medivir
Phase 1/2 Terminated
NCT01943461 2020-09-30
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03539484 2020-09-03
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT01369433 2020-09-01
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
AVEO Pharmaceuticals, Inc.
Phase NA Terminated
NCT01832506 2020-08-06
A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT01525602 2020-07-16
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Completed
NCT01862328 2020-06-22
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
Takeda
Phase 1 Completed
NCT02451007 2019-11-19
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
PharmaMar
Phase 2 Completed
NCT01215916 2019-03-15
A Phase 1 Study in Patients With Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT01341457 2019-03-01
A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT01431534 2019-03-01
MK-8669-056
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01634555 2019-02-26
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
Eli Lilly and Company
Phase 2 Completed
NCT01214668 2019-01-04
Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT01463696 2018-08-27
Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01955473 2017-08-23
Japanese Phase 1 Trial of Sym004 in Solid Tumors
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT01624467 2016-07-25
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT02063230 2016-07-21
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
AstraZeneca
Phase 1 Completed
NCT00658658 2016-05-18
Panitumumab in Children With Solid Tumors
Amgen
Phase 1 Completed
NCT00798889 2013-01-21
Rollover Protocol for Prior SU011248 Protocols
Pfizer
Phase NA Completed
NCT00424632 2012-06-25
Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed